Only ~20% of patients with advanced non–small-cell lung cancer will benefit from immunotherapy; thus, biomarkers are needed. We performed a retrospective analysis of peripheral blood biomarker expression in 154 patients with advanced non–small-cell lung cancer receiving immunotherapy. Five variables at baseline (smoking, Eastern Cooperative Oncology Group performance status, liver metastases, lactate dehydrogenase, and neutrophil/lymphocyte ratio) were combined in a prognostic score (EpSILoN), which significantly identified 3 prognostic groups.
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
Bilancia M.;
2020-01-01
Abstract
Only ~20% of patients with advanced non–small-cell lung cancer will benefit from immunotherapy; thus, biomarkers are needed. We performed a retrospective analysis of peripheral blood biomarker expression in 154 patients with advanced non–small-cell lung cancer receiving immunotherapy. Five variables at baseline (smoking, Eastern Cooperative Oncology Group performance status, liver metastases, lactate dehydrogenase, and neutrophil/lymphocyte ratio) were combined in a prognostic score (EpSILoN), which significantly identified 3 prognostic groups.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1525730419303341-main.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright dell'editore
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
